Novo Nordisk's Wegovy® (semaglutide) demonstrated significant weight loss averaging 22.6% in premenopausal women and consistent results across all menopause stages, with major reductions in waist circumference. The drug also lowered risks of migraines by 42-45% and depression by 25% compared to menopausal hormone therapy alone. Additionally, Wegovy® reduced cardiovascular risks, including heart attacks and strokes, especially in perimenopausal women. These findings highlight Wegovy®'s potential to improve metabolic health and quality of life for women with obesity during menopause, addressing both physical and mental health challenges.
Novo Nordisk's Wegovy pill (oral semaglutide 25 mg) demonstrated significant weight loss and mobility improvements in adults with obesity in the phase 3 OASIS 4 trial. Nearly 29% of early responders lost an average of 21.6% body weight by week 64, wh...
Novo Nordisk disclosed that two closely associated persons of its CFO, Karsten Munk Knudsen, received 50 shares each as gifts on May 7, 2026. The shares were valued around DKK 294 per share and the transactions occurred outside a trading venue. This ...
Telehealth company Hims & Hers saw its stock fall 15.7% in premarket trading after reporting a first-quarter net loss of $92 million, nearly double last year's $50 million loss. Revenue rose 4% to $608 million, but average monthly revenue per subscri...
Novo Nordisk's STEP UP trial shows that the higher 7.2 mg dose of Wegovy (semaglutide) enables early responders to lose an average of 27.7% body weight after 72 weeks, significantly more than the 2.4 mg dose or placebo. Most weight loss came from fat...
Novo Nordisk reported strong first-quarter results, driven by a better-than-expected launch of its Wegovy GLP-1 pill. Citi raised its target price to DKK290, reflecting modest earnings upgrades for 2027-2031, but maintained a neutral rating due to co...
